Skip to main content

Surgical Blood Loss

2
Pipeline Programs
4
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
Fibrinogen ConcentratePhase 3
Martin Pharmaceuticals
1 program
1
Tranexamic AcidPhase 31 trial
Active Trials
NCT06414031Recruiting850Est. Nov 2026
CSL Behring
CSL BehringIL - Bradley
1 program
Fibrinogen ConcentratePHASE_31 trial
Active Trials
NCT01475669Completed152Est. Sep 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Martin PharmaceuticalsTranexamic Acid
CSL BehringFibrinogen Concentrate

Clinical Trials (2)

Total enrollment: 1,002 patients across 2 trials

Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery

Start: Jun 2024Est. completion: Nov 2026850 patients
Phase 3Recruiting
NCT01475669CSL BehringFibrinogen Concentrate

Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery

Start: Jan 2012Est. completion: Sep 2014152 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,002 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.